Evidence map›Paper›PMID 41148264›Full record

ArticleWorld journal of urology2025

Outcomes of aquablation: pooled analysis from the WATER, WATER II, OPEN WATER, FRANCAIS WATER, and JAPAN PMS studies.

Mario Henrique Bitar Siqueira, Mohamad Baker Berjaoui, Naeem Bhojani, Alex Te, Peter Gilling, Gopal Badlani, Neil Barber, Thorsten Bach, Vincent Misrai, Nobuyuki Hinata and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mario Henrique Bitar SiqueiraDivision of Urology, University of Toronto, University Health Network, Toronto Western Hospital, Room 317, 8th Floor,Main Pavilion, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.
Mohamad Baker BerjaouiDivision of Urology, University of Toronto, University Health Network, Toronto Western Hospital, Room 317, 8th Floor,Main Pavilion, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.
Naeem BhojaniUniversity of Montreal Hospital Center, Université de Montréal, Montreal, Canada.
Alex TeDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, USA.
Peter GillingDepartment of Urology, Tauranga Hospital, Tauranga, New Zealand.
Gopal BadlaniDepartment of Urology, Wake Forest University, Winston Salem, USA.
Neil BarberDepartment of Urology, Frimley Park Hospital, Frimley, UK.
Thorsten BachSchool of Natural Sciences, Department of Chemistry and Catalysis Research Center, Technical University of Munich, Garching, Germany.
Vincent MisraiDepartment of Urology, Clinique Pasteur, Toulouse, France.
Nobuyuki HinataDepartment of Urology, Roswell Park Cancer Institute, Buffalo, USA.
Shin KoikeDepartment of Urology, Itabashi Chuo Medical Center JP, Tokyo, Japan.
Dean EltermanDivision of Urology, University of Toronto, University Health Network, Toronto Western Hospital, Room 317, 8th Floor,Main Pavilion, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada. dean.elterman@uhn.ca.ORCID http://orcid.org/0000-0003-1507-7783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAquablation is a novel surgical technique for the treatment of benign prostatic hyperplasia (BPH).This analysis consolidates data from five international studies-WATER, WATER II, OPEN WATER, FRANCAIS WATER, and JAPAN PMS-to evaluate the long-term efficacy and safety of Aquablation.

methodsData from 528 patients with symptomatic BPH were pooled from five prospective, multinational studies. Outcomes included International Prostate Symptom Score (IPSS), quality of life (QoL), peak urinary flow rate (Qmax), and post-void residual volume (PVR). Measurements were recorded at baseline and at 1-, 3-, 6-, and 12-months post-procedure.

resultsAt baseline, patients had a mean age of 67.8 ± 7.7 years and a mean prostate volume of 71.7 ± 32.0 mL (range 20-242 ml). The mean IPSS decreased significantly from 21.5 ± 7.3 at baseline to 5.8 ± 5.0 at 6 months and stabilized at 6.6 ± 5.5 by 12 months. QoL scores improved from 4.7 ± 1.2 at baseline to 1.4 ± 1.5 at 6 and 12 months. Qmax increased from 8.1 ± 5.0 mL/s to 19.0 ± 11.1 mL/s at 3 months and 20.5 ± 11.0 mL/s at 12 months. PVR decreased from 105.9 ± 106.9 mL at baseline to 53.1 ± 68.1 mL at 12 months. Voided volume improved from 197.5 ± 101.9 mL at baseline to 271.9 ± 151.9 mL at 12 months.

conclusionAquablation demonstrates sustained improvements in BPH symptoms, quality of life, and urodynamic parameters over a 12-month period. This analysis supports Aquablation as a safe and effective treatment for BPH.

Indexed as

Ablation TechniquesProstatic HyperplasiaAgedAquablationHumansJapanMaleMiddle AgedProspective StudiesQuality of LifeTreatment OutcomeWaterWaterAquablationBenign prostatic hyperplasiaLong-term outcomesRobotic-assisted surgery

Identifiers

PMID41148264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.